Nikita Patel cuts stake in Bacil Pharma by 7.1%

Nikita Hiren Patel reduced her shareholding in Bacil Pharma Limited by 7.1% through an open-market disposal of shares on June 22 and June 23, 2026. The transaction was disclosed to the Bombay Stock Exchange Limited under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the disposal, Patel held 24,63,896 shares, representing 17.17% of the total voting capital. The sale of 10,19,052 shares reduced her total holding to 14,44,844 shares, which constitutes 10.07% of the company's voting capital. Bacil Pharma's total equity share capital remains unchanged at 1,43,53,000 equity shares of ₹10 each.

The disclosure confirmed that the acquirer does not belong to the promoter or promoter group of the target company. The total diluted share capital of the company was reported as NA following the transaction. The filing was submitted by Mrs. Nikita Hiren Patel as the authorised signatory.

Shareholding Details

The following table outlines the changes in Patel's shareholding:

Description	Number of Shares	% of Total Share Capital	% of Total Diluted Share Capital
Holding Before Disposal
Shares carrying voting rights	24,63,896	17.17%	17.17%
Shares Disposed
Shares sold	10,19,052	7.10%	7.10%
Holding After Disposal
Shares carrying voting rights	14,44,844	10.07%	10.07%

The mode of sale was specified as open-market transactions. The equity share capital of Bacil Pharma Limited before and after the disposal stood at 1,43,53,000 equity shares.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.82%	-3.37%	-5.09%	-14.54%	-0.72%	+461.05%

bacil pharma proposes to incorporate a wholly-owned subsidiary named Bacil Research & Development Private Limited to strengthen its research and development capabilities. The new entity will be established as a private limited company and will focus on undertaking R&D activities and other allied operations permitted under applicable laws. The incorporation is subject to approval from the Registrar of Companies and other relevant statutory authorities.

The Board of Bacil Pharma Limited has identified the need for a dedicated subsidiary to drive its research initiatives. This strategic move aims to enhance the company's focus on developing new products and technologies. The subsidiary will operate entirely under the ownership of Bacil Pharma Limited, ensuring direct control over its research outcomes.

Key Details of the Proposed Subsidiary

Detail	Information
Name	Bacil Research & Development Private Limited
Structure	Private Limited Company
Ownership	Wholly-owned by Bacil Pharma Limited
Objective	Research and development activities and allied operations
Status	Subject to regulatory approvals

The intimation was submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mrs. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited, signed the communication regarding the proposal.